Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Oncternal Therapeutics's 10-Year RORE % for the quarter that ended in Sep. 2024 was -45.09%.
The industry rank for Oncternal Therapeutics's 10-Year RORE % or its related term are showing as below:
ONCT's 10-Year RORE % is not ranked
in the Biotechnology industry.
Industry Median: -6.43
vs ONCT: -45.09
Oncternal Therapeutics 10-Year RORE % Historical Data
The historical data trend for Oncternal Therapeutics's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Oncternal Therapeutics's 10-Year RORE %
For the Biotechnology subindustry, Oncternal Therapeutics's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncternal Therapeutics's 10-Year RORE % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Oncternal Therapeutics's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 10-year before.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Oncternal Therapeutics 10-Year RORE % Related Terms
Thank you for viewing the detailed overview of Oncternal Therapeutics's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ONCT has been successfully added to your 